| Objective To evaluate the efficacy and safety of alendronate combined with atorvastatin in diabetes mellitus with osteoporosis. Methods A systematic review and meta-analysis was performed by searching in the Science, Web of Science, PubMed, Cochrane Central Register of Controlled Trials, Joanna Briggs Institute Library, MEDLINE, CNKI, Web of Knowledge, Wanfang Data Selection criteria for studies: Randomized controlled trials (RCT) and controlled clinical trials (CCT) comparing alendronate combined with atorvastatin with atorvastatin in patients with diabetes mellitus with osteoporosis. Data were extracted independently by the reviewers who had evaluated the literature quality. Meta-analysis was performed with the RevMan 5.3 software. Results 15 studies were included, six RCTs and nine CCTs were eventually identified for the meta-analysis, with 1 420 patients in total. Meta-analysis showed that, compared with the atorvastatin group, alendronate combined with atorvastatin could significantly increase bone density, pain relief efficiency and the level of N-MID, BAP and OPG and reduce the pain score and adverse reactions incidence. However, no significant differences were observed in blood phosphorus, blood calcium, BGP and glycosylated hemoglobin between two groups. Conclusion Alendronate combined with atorvastatin could increase bone density and relieve pain. Alendronate combined with atorvastatin should be recommended for the diabetes mellitus and osteoporosis patients. |